# Lisa A. Beck

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/lisa-a-beck/

## Facts

| Field | Value |
| --- | --- |
| Citations | 27,512 |
| Field | Dermatology and Skin Diseases |
| h-index | 78 |
| i10-index | 178 |
| Last Known Institution | University of Rochester Medicine |
| OpenAlex ID | https://openalex.org/A5081892653 |
| ORCID iD | https://orcid.org/0000-0002-8452-667X |
| Works | 449 |

## Researcher papers

Showing 12 of 17.

- [Guidelines for the Diagnosis and Management of Food Allergy in the United States: Summary of the NIAID-Sponsored Expert Panel Report](https://scholariq.org/papers/guidelines-for-the-diagnosis-and-management-of-food-allergy-in-the-united-states/)
- [Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis](https://scholariq.org/papers/two-phase-3-trials-of-dupilumab-versus-placebo-in-atopic-dermatitis/)
- [Atopic dermatitis](https://scholariq.org/papers/atopic-dermatitis-2/)
- [Dupilumab Treatment in Adults with Moderate-to-Severe Atopic Dermatitis](https://scholariq.org/papers/dupilumab-treatment-in-adults-with-moderate-to-severe-atopic-dermatitis/)
- [Cytokine modulation of atopic dermatitis filaggrin skin expression](https://scholariq.org/papers/cytokine-modulation-of-atopic-dermatitis-filaggrin-skin-expression/)
- [Tight junction defects in patients with atopic dermatitis](https://scholariq.org/papers/tight-junction-defects-in-patients-with-atopic-dermatitis/)
- [Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial](https://scholariq.org/papers/efficacy-and-safety-of-dupilumab-in-adults-with-moderate-to-severe-atopic/)
- [Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis](https://scholariq.org/papers/efficacy-and-safety-of-dupilumab-in-adolescents-with-uncontrolled-moderate-to/)
- [Addendum guidelines for the prevention of peanut allergy in the United States: Report of the National Institute of Allergy and Infectious Diseases–sponsored expert panel](https://scholariq.org/papers/addendum-guidelines-for-the-prevention-of-peanut-allergy-in-the-united-states/)
- [Cytokine modulation of atopic dermatitis filaggrin skin expression](https://scholariq.org/papers/cytokine-modulation-of-atopic-dermatitis-filaggrin-skin-expression-2/)
- [Atopic dermatitis: A practice parameter update 2012](https://scholariq.org/papers/atopic-dermatitis-a-practice-parameter-update-2012/)
- [Efficacy and safety of dupilumab with concomitant topical corticosteroids in children 6 to 11 years old with severe atopic dermatitis: A randomized, double-blinded, placebo-controlled phase 3 trial](https://scholariq.org/papers/efficacy-and-safety-of-dupilumab-with-concomitant-topical-corticosteroids-in/)

## Researcher topics

- [Dermatology and Skin Diseases](https://scholariq.org/topics/dermatology-and-skin-diseases/)
- [Asthma and respiratory diseases](https://scholariq.org/topics/asthma-and-respiratory-diseases/)
- [Urticaria and Related Conditions](https://scholariq.org/topics/urticaria-and-related-conditions-2/)
- [Allergic Rhinitis and Sensitization](https://scholariq.org/topics/allergic-rhinitis-and-sensitization/)
- [Food Allergy and Anaphylaxis Research](https://scholariq.org/topics/food-allergy-and-anaphylaxis-research/)

## Researcher university

- [University of Rochester Medicine](https://scholariq.org/institutions/university-of-rochester-medicine/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.